Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 1, 2011, Pages 31-35

  Mori, Takahiro ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clinical trial; CTLA 4; Fully human monoclonal antibody; Melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG PROTEIN BINDING; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC HORMONE REFRACTORY PROSTATE CANCER; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

EID: 79957569796     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chambers CA and Allison JP: CTLA - the costimulatory molecule that doesn't: Regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 64: 303-312, 1999.
2. Chambers CA, Kuhns MS, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594, 2001.
3. Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996. (Pubitemid 26102823)
4. Pentcheva-Hoang T, Egen JG, Wojnoonski K, et al: B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21: 401-413, 2004. (Pubitemid 39208341)
5. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100(8): 4712-4717, 2003. (Pubitemid 36457795)
6. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100(14): 8372-8377, 2003.
7. Tomillero A and Moral MA: Gateways to clinical trials. Methods Find Exp Clin Pharmacol 30(8): 643-672, 2008.
8. Poust J: Targeting metastatic melanoma. Am J Health Syst Pharm 65 (24 suppl 9): S9-S15, 2008.
9. Ribas A, Hanson DC, Noe DA, et al: Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12(7): 873-883, 2007. (Pubitemid 47328230)
10. Healey DT, Carlson PS, Huang B, et al: Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15-suppl (May 20 Supplement): 2574, 2010.
11. Camacho LH, Antonia S, Sosman, J, et al: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27(7): 1075-1081, 2009.
12. Kirkwood JM, Lorigan P, Hersey P, et al: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16 (3): 1042-1048, 2010.
13. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma. Medarex, Inc., 2007-12-10.
14. Surprise' prostate result probed. BBC News, 2009-06-19.
15. Mayo Researchers: Dramatic Outcomes in Prostate Cancer Study. Mayo Clinic, 2009-06-19.
16. O'Day SJ, Hodi FS, McDermott DF, et al: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. ASCO 2010, abstr No. 4.
17. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723, 2010.
18. Wolchok JD, Neyns B, Linette G, et al: Iplimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164, 2010.
19. Lynch T, Bondarenko I, Luft A, et al: Phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in firstline stage IIb/IV non-small cell lung cancer (NSCLC) (study CA 184-041). ASCO 2010, abstr No. 7531.
20. Tollefson MK, Kames RJ, Thompson RH, et al: A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. ASCO GU 2010, abstr No. 168.